Immunoproliferative Disorders
Showing 1 - 25 of >10,000
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders Trial in Chapel Hill (iC9-CAR19 cells,
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- iC9-CAR19 cells
- +3 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 21, 2022
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)
Recruiting
- Lymphoma
- +7 more
- ATLCAR.CD30 cells
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022
Lymphoma, Lymphoma, B-Cell, Immune System Diseases Trial in Chapel Hill (iC9-CAR19 T cells, Bendamustine, Fludarabine)
Recruiting
- Lymphoma
- +4 more
- iC9-CAR19 T cells
- +4 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022
Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)
Not yet recruiting
- Lymphoma, Mantle-Cell
- +7 more
- Zilovertamab
- +2 more
- (no location specified)
Jun 21, 2022
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 cells)
Active, not recruiting
- Hodgkin Disease
- +8 more
- ATLCAR.CD30 cells
-
Chapel Hill, North Carolina
- +1 more
Mar 2, 2022
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders Trial in Chapel Hill (iC9-CAR19 cells,
No longer available
- Acute Lymphoblastic Leukemia
- +2 more
- iC9-CAR19 cells
- +3 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2021
Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)
Active, not recruiting
- Multiple Myeloma
- +19 more
- CYNK-001
-
Denver, Colorado
- +8 more
May 24, 2022
Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)
Not yet recruiting
- Relapsed/Refractory Aggressive B-Cell Malignancies
- ONCT-808
- Bridging Therapy
- (no location specified)
Jan 19, 2023
Acute Myeloid Leukemia Trial in United Kingdom, United States (Arm 1: NTLA-5001, Arm 2: NTLA-5001)
Terminated
- Acute Myeloid Leukemia
- Arm 1: NTLA-5001
- Arm 2: NTLA-5001
-
Los Angeles, California
- +9 more
Oct 13, 2022
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022
Not yet recruiting
- Cancer
- Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Fludarabine (30 mg/m^2)
- +2 more
- (no location specified)
Jul 25, 2023
Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory DLBCL Trial in Canada (DPX-Survivac, Pembrolizumab,
Active, not recruiting
- Adult Diffuse Large Cell Lymphoma
- +2 more
- DPX-Survivac
- +2 more
-
Calgary, Alberta, Canada
- +5 more
Nov 9, 2022
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia Trial in United States (drug, procedure, other, radiation)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +10 more
- Busulfan
- +10 more
-
Jacksonville, Florida
- +5 more
Aug 14, 2023
Follicular Lymphoma (Gastric or Duodenal), Marginal Zone Lymphoma (Gastric or Duodenal) Trial in Münster (Radiation Therapy)
Recruiting
- Follicular Lymphoma (Gastric or Duodenal)
- Marginal Zone Lymphoma (Gastric or Duodenal)
- Radiation Therapy
-
Münster, North Rhine-Westphalia, GermanyDepartment of Radiation Oncology
Dec 1, 2021
Lymphoma Epidemiology of Outcomes Cohort Years 6-10
Enrolling by invitation
- Lymphoma, Non-Hodgkin
-
Miami, Florida
- +7 more
Aug 20, 2021
Activated B-cell DLBCL (ABC DLBCL) Trial in United Kingdom, United States (Acalabrutinib)
Active, not recruiting
- Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
-
Los Angeles, California
- +6 more
Dec 1, 2022
Acute Leukemia, MDS, T-lymphoblastic Lymphoma Trial (drug, radiation, procedure)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +6 more
- Bone Marrow Hematopoeitic Cell Transplant (HCT)
- +9 more
- (no location specified)
Sep 27, 2021
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia Trial in San Francisco (CD34+ enriched, T Cell
No longer available
- Acute Lymphoblastic Leukemia
- +11 more
- CD34+ enriched, T Cell Depleted donor stem cell product
-
San Francisco, CaliforniaUniversity of California, San Francisco
May 25, 2021
B-precursor Acute Lymphoblastic Leukemia, ALL, GNR-084 Trial in Moscow, Saint Petersburg (GNR-084, 0.01 ng/kg, GNR-084, 0.1
Recruiting
- B-precursor Acute Lymphoblastic Leukemia
- +2 more
- GNR-084, 0.01 ng/kg
- +5 more
-
Moscow, Russian Federation
- +2 more
Oct 25, 2021
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (drug,
Recruiting
- Acute Lymphoblastic Leukemia
- +7 more
- Busulfan
- +11 more
-
Duarte, California
- +26 more
Aug 11, 2022
Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,
Recruiting
- Waldenstrom Macroglobulinemia
- +8 more
- Iopofosine I 131 single dose
- +2 more
-
Redlands, California
- +42 more
Dec 30, 2022
Cutaneous T-Cell Lymphoma/Mycosis Fungoides Trial in Belgium, France, United States (Cobomarsen)
Terminated
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
-
Phoenix, Arizona
- +8 more
Nov 17, 2020
Mental Disorders: Application of a Multi-modal & Domains System
Not yet recruiting
- Mental Disorder
-
Shanghai, Shanghai, ChinaShanghai Mental Health Center
Jul 2, 2023
"Functional Overlay" in Patients With Movement Disorders
Recruiting
- Conversion Disorder
- +3 more
- Neurological examination
- +4 more
-
Graz, Styria, AustriaMedical University of graz
Jul 5, 2023